Structure Therapeutics (GPCR) Liabilities and Shareholders Equity (2022 - 2026)

Structure Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 74.04% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 29.88% YoY), while the FY2025 annual figure was $1.6 billion, up 75.34% from the prior year.
• Liabilities and Shareholders Equity was $1.5 billion for Q1 2026 at Structure Therapeutics, down from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q4 2025 to a low of $97.8 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $722.9 million across 5 years, with a median of $824.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity soared 392.63% in 2023, then retreated 13.79% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $97.8 million in 2022, then jumped by 392.63% to $482.0 million in 2023, then jumped by 87.41% to $903.3 million in 2024, then soared by 75.34% to $1.6 billion in 2025, then dropped by 4.79% to $1.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $832.2 million (Q3 2025), per Business Quant data.